Medgen announces human study of Wide Awake Energy Spray

Medgen, Inc. (OTCPink: MDIN) today announced that it is preparing to start a study regarding the use of Wide Awake™ Energy Spray, the highly unique and popular caffeinated fresh breath spray. The company expects the study to begin February 1, 2016.

Manufacturers of dietary supplements and dietary ingredients like those contained in Wide Awake™ are prohibited from marketing products that are not properly branded, or make claims that they cannot back up. That means that Medgen is responsible for evaluating the safety and labeling of its products to be sure that they meet all the requirements of the Dietary Supplement Health and Education Act of 1994 (DSHEA) and FDA regulations in Section 21 CFR part 111 governing dietary supplements.

The study will last 14 days, and will be made up of a cross section of up to 100 individuals who will receive a bottle of Wide Awake™ to use as they feel fit. Within that population will be a control group of people who receive non-caffeinated breath spray so that the actual results and patterns of use can be tracked and quantified. CEO, Matthew Briggs commented, “We want to know exactly where the product stands with users, and what its true effectiveness really is. A small group of insiders have tested it and we use outside research focused on the ingredients to determine what is effective and what is not as effective, but a larger study that will allow us to track specific statistics will help us tremendously to gauge this products potential, as well as giving us real leverage with retailers. If the results come back as good as we think they will, then this product will be the one that makes Medgen great again.”

Anyone interested in being part of the study can apply by emailing Applicants should be aware that the company may not be using everyone that applies, however because a group of subjects has already been identified and the study must contain an even mix of individuals of genders and different geographic locations. This is the first such study the company has done in over ten years and marks the beginning of a new phase for Medgen. Next, the company has its sights set on a more modern study of SNORenz in partnership with an experienced sleep study laboratory, but details have yet to be announced as they materialize. The company feels that with hard data, it will get better distribution deals and target it marketing more effectively in preparation for the biggest push towards global distribution in the company’s history.

About Medgen, Inc. Medgen is dedicated to producing the best alternative healthcare products to the world. The company’s products include SNORenz®, SNORenz Night Time™, Stem-Intense™, and more. Most of the company’s products use a unique or patented spray delivery system, and all have received rave consumer reviews all over the world, selling millions of units from 1996 to the present. For more info the company encourages people to check out or follow the company on twitter at @medgeninc.

DISCLAIMER This Press Release may contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The Company has tried, whenever possible, to identify these forward-looking statements using words such as “anticipates,” “believes,” “estimates,” “expects,” “plans,” “intends,” “potential” and similar expressions. These statements reflect the Company’s current beliefs and are based upon information currently available to it. Accordingly, such forward-looking statements involve known and unknown risks, uncertainties and other factors which could cause the Company’s actual results, performance or achievements to differ materially from those expressed in or implied by such statements. The Company undertakes no obligation to update or advise in the

Leave a Reply

Your email address will not be published. Required fields are marked *